Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors.

Li B, Orton D, Neitzel LR, Astudillo L, Shen C, Long J, Chen X, Kirkbride KC, Doundoulakis T, Guerra ML, Zaias J, Fei DL, Rodriguez-Blanco J, Thorne C, Wang Z, Jin K, Nguyen DM, Sands LR, Marchetti F, Abreu MT, Cobb MH, Capobianco AJ, Lee E, Robbins DJ.

Sci Signal. 2017 Jun 27;10(485). pii: eaak9916. doi: 10.1126/scisignal.aak9916.

2.

Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo.

Werfel TA, Jackson MA, Kavanaugh TE, Kirkbride KC, Miteva M, Giorgio TD, Duvall C.

J Control Release. 2017 Jun 10;255:12-26. doi: 10.1016/j.jconrel.2017.03.389. Epub 2017 Mar 31.

3.

Cortactin promotes exosome secretion by controlling branched actin dynamics.

Sinha S, Hoshino D, Hong NH, Kirkbride KC, Grega-Larson NE, Seiki M, Tyska MJ, Weaver AM.

J Cell Biol. 2016 Jul 18;214(2):197-213. doi: 10.1083/jcb.201601025. Epub 2016 Jul 11.

4.

Repairing Fetal Membranes with a Self-adhesive Ultrathin Polymeric Film: Evaluation in Mid-gestational Rabbit Model.

Pensabene V, Patel PP, Williams P, Cooper TL, Kirkbride KC, Giorgio TD, Tulipan NB.

Ann Biomed Eng. 2015 Aug;43(8):1978-88. doi: 10.1007/s10439-014-1228-9. Epub 2014 Dec 31.

5.

Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers.

Miteva M, Kirkbride KC, Kilchrist KV, Werfel TA, Li H, Nelson CE, Gupta MK, Giorgio TD, Duvall CL.

Biomaterials. 2015 Jan;38:97-107. doi: 10.1016/j.biomaterials.2014.10.036. Epub 2014 Nov 1.

6.

Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery.

Li H, Miteva M, Kirkbride KC, Cheng MJ, Nelson CE, Simpson EM, Gupta MK, Duvall CL, Giorgio TD.

Biomacromolecules. 2015 Jan 12;16(1):192-201. doi: 10.1021/bm501394m. Epub 2014 Dec 19.

7.

Exosome secretion is enhanced by invadopodia and drives invasive behavior.

Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Grega-Larson N, Tyska MJ, Weaver AM.

Cell Rep. 2013 Dec 12;5(5):1159-68. doi: 10.1016/j.celrep.2013.10.050. Epub 2013 Nov 27.

8.

Regulation of late endosomal/lysosomal maturation and trafficking by cortactin affects Golgi morphology.

Kirkbride KC, Hong NH, French CL, Clark ES, Jerome WG, Weaver AM.

Cytoskeleton (Hoboken). 2012 Sep;69(9):625-43. doi: 10.1002/cm.21051. Epub 2012 Jul 31.

9.

Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC.

Neoplasia. 2011 Aug;13(8):758-70.

10.

Cortactin: a multifunctional regulator of cellular invasiveness.

Kirkbride KC, Sung BH, Sinha S, Weaver AM.

Cell Adh Migr. 2011 Mar-Apr;5(2):187-98. Epub 2011 Mar 1. Review.

11.

The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors.

Lee NY, Kirkbride KC, Sheu RD, Blobe GC.

Mol Biol Cell. 2009 Oct;20(20):4362-70. doi: 10.1091/mbc.E09-07-0539. Epub 2009 Sep 2.

12.

Human-in-mouse modeling of primary head and neck squamous cell carcinoma.

Law JH, Whigham AS, Wirth PS, Liu D, Pham MQ, Vadivelu S, Kirkbride KC, Brown BT, Burkey BB, Sinard RJ, Netterville JL, Yarbrough WG.

Laryngoscope. 2009 Dec;119(12):2315-23. doi: 10.1002/lary.20607.

PMID:
19693929
13.

Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2.

Gordon KJ, Kirkbride KC, How T, Blobe GC.

Carcinogenesis. 2009 Feb;30(2):238-48. doi: 10.1093/carcin/bgn274. Epub 2008 Dec 4.

14.

Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.

Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC.

J Biol Chem. 2008 Mar 21;283(12):7628-37. doi: 10.1074/jbc.M704883200. Epub 2008 Jan 9.

15.

The type III TGF-beta receptor suppresses breast cancer progression.

Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC.

J Clin Invest. 2007 Jan;117(1):206-17. Epub 2006 Dec 7.

16.

Cell-surface co-receptors: emerging roles in signaling and human disease.

Kirkbride KC, Ray BN, Blobe GC.

Trends Biochem Sci. 2005 Nov;30(11):611-21. Epub 2005 Sep 26. Review.

PMID:
16185874
17.

Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling.

Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC.

Science. 2003 Sep 5;301(5638):1394-7.

18.

Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy.

Kirkbride KC, Blobe GC.

Expert Opin Biol Ther. 2003 Apr;3(2):251-61. Review.

PMID:
12662140

Supplemental Content

Loading ...
Support Center